最新消息

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.以開發創新免疫生物藥物的全球臨床階段生技公司-漢康生技今天宣布，台灣衛生福利部食品藥物管理署 (TFDA) 已批准其在研新藥申請 (IND)，以開展獨立研發的新藥候選物 HCB101 的多區域臨床試驗，用於治療晚期實體瘤或復發難治性非霍奇金淋巴瘤患者。

1. 為何會創立漢康生技？2. 漢康生技創立的時間跟宗旨是？3. 目前為止，漢康生技已獲得哪些研發的成果或是募資上的成功？4. 漢康生技的願景是甚麼?5. 針對生物科技、醫療相關領域，漢康生技能為社會做些甚麼？6. 漢康生技所研發的藥物跟其他傳統藥物的最大區別跟優勢是？關鍵技術是？7. FBDB™是甚麼？特別之處是？它對研發上有哪些幫助？8. 預計受惠者的規模或是程度為何？9. 像這樣多種靶向模式的生物製劑，以重啟免疫系統來對抗疾病的機轉，是否能應用於其他疾病或醫學領域？

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.漢康生技（HanchorBio Inc.），一家專注於腫瘤免疫治療新藥研發與臨床的全球生技公司，今日宣佈其自主研發的創新融合蛋白HCB101獲得美國食品藥物管理局（FDA）授予新藥臨床試驗（IND）許可，即將開展多地區多中心的臨床試驗。此藥將用於治療晚期實體瘤及復發難治癒的非霍奇金淋巴瘤。

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。

HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-medicines, completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023 in Taipei, Taiwan with world-renowned professors and few Board of Director (BOD) members.

Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States.

At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.2022年8月5日，漢康生技——一家致力於成為開發下一代免疫療法先驅者的生物技術公司，宣佈成功完成了約計2000萬美金的A輪融資交割。本次A輪融資的資金將使漢康生技能夠進一步擴大和加速其不斷增長的專有“基於Fc設計的生物製藥（FBDB™）”管線研發進程，並將進一步支援擬申報新藥在臨床前研究階段（IND-enabling）的GLP毒理研究、新藥申報以及後續第一部分的臨床I期試驗。